文章：

胶质母细胞瘤免疫治疗模式综合评述：作用机制、疗效与安全性考量†

A Comprehensive Review of Immunotherapeutic Modalities in Glioblastoma: Mechanisms, Efficacy, and Safety Considerations†

原文发布日期：9 January 2026

DOI: 10.3390/cancers18020212

类型: Article

开放获取: 是

英文摘要：

Background: Glioblastoma multiforme (GBM), the most aggressive primary brain malignancy in adults, is associated with poor prognosis and recurrence despite standard of care and newer immunotherapies. This warrants exploration of synergistic approaches such as combination immunotherapy for improved tumor control. Methods: We initiated a systematic review of articles from 2015–2025 in PubMed, Embase, Scopus, Cochrane, and Web of Science if they assessed immunotherapy for GBM. Results: We included 49 studies (n = 3002 patients) with no significant demographic differences across publications. Combination immunotherapy regimens demonstrated higher pooled ORRs in limited comparative analyses, though findings were driven by a small number of studies. Single-arm analysis for overall survival (OS), progression-free survival (PFS), treatment-related adverse events (TRAEs), and ORR showed no significant differences among the groups. However, treatment–control arm analysis showed pooled ORs of 9.51 for combination immunotherapies and 0.44 in the control group. Conclusions: Combining immunotherapeutics across mechanisms may potentiate immune response effectiveness against GBM.

摘要翻译： 

背景：胶质母细胞瘤（GBM）是成人中最具侵袭性的原发性脑部恶性肿瘤，即使采用标准疗法和新型免疫治疗，其预后仍然不良且易复发。这促使我们探索协同治疗策略，例如联合免疫疗法，以提升肿瘤控制效果。方法：我们对2015年至2025年间PubMed、Embase、Scopus、Cochrane及Web of Science数据库中评估GBM免疫疗法的文章进行了系统性综述。结果：共纳入49项研究（涉及3002例患者），各文献间人口学特征无显著差异。在有限的比较分析中，联合免疫疗法方案显示出更高的总客观缓解率，但该结果主要由少量研究驱动。针对总生存期、无进展生存期、治疗相关不良事件及客观缓解率的单臂分析显示，各组间无显著差异。然而，治疗-对照组分析表明，联合免疫疗法的汇总比值比为9.51，对照组为0.44。结论：跨机制联合免疫治疗可能增强针对GBM的免疫应答效能。

原文链接：

A Comprehensive Review of Immunotherapeutic Modalities in Glioblastoma: Mechanisms, Efficacy, and Safety Considerations†